Holen Sie sich die Stockscreener-App
16.97
0.37%
-0.07
Schlusskurs vom Vortag:
$17.04
Offen:
$17.04
24-Stunden-Volumen:
142.81K
Relative Volume:
0.32
Marktkapitalisierung:
$541.36M
Einnahmen:
$219.79M
Nettoeinkommen (Verlust:
$-57.47M
KGV:
-7.893
EPS:
-2.15
Netto-Cashflow:
$-19.25M
1W Leistung:
+2.14%
1M Leistung:
-13.83%
6M Leistung:
-46.62%
1J Leistung:
-29.99%
1-Tages-Spanne:
$16.55
$17.14
1-Wochen-Bereich:
$16.55
$17.70
52-Wochen-Spanne:
$15.70
$35.84
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX
Vergleichen Sie CSTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
16.97 | 541.36M | 219.79M | -57.47M | -19.25M | -2.15 |
|
TMO
Thermo Fisher Scientific Inc
|
428.92 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.39 | 136.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
507.09 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.31 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.48 | 26.35B | 15.50B | 1.33B | 2.16B | 7.34 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences confirms UM test’s efficacy - Investing.com
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Ri - GuruFocus
Castle Biosciences confirms UM test’s efficacy By Investing.com - Investing.com South Africa
Castle Biosciences to buy Previse - MSN
Castle Biosciences Reports Independent Validation of DecisionDx-UM Test with PRAME Gene Expression Data at ARVO 2025 - Nasdaq
Real-World Study Confirms Long-Term Performance of - GlobeNewswire
Texas public company to acquire Baltimore cancer diagnostic firm - The Business Journals
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences (CSTL) Champions Skin Cancer Awareness Initiatives | CSTL Stock News - GuruFocus
Castle Biosciences Partners with Melanoma Organizations to Promote Skin Cancer Awareness and Education in May - Nasdaq
Castle Biosciences Celebrates Skin Cancer Awareness Month - GlobeNewswire
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowe - GuruFocus
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowered | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Re - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Revenue Report | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Receives Price Target Adjustment by Ca - GuruFocus
Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | C - GuruFocus
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Castle Biosciences (CSTL) Receives Price Target Adjustment by Canaccord Genuity | CSTL Stock News - GuruFocus
Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse - FinSMEs
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Yahoo Finance
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: - GuruFocus
Castle Biosciences Reports Strong Q1 2025 Growth - TipRanks
Castle Biosciences to Acquire GI Health Company Previse - HIT Consultant
castle biosciences inc. Positive Earnings Pre-Announcements - RTTNews
Earnings call transcript: Castle Biosciences Q1 2025 revenue growth surpasses expectations - Investing.com Nigeria
Castle Biosciences (CSTL) to Acquire Gastrointestinal Firm Previ - GuruFocus
Castle Biosciences (CSTL) Adjusts 2025 Revenue Outlook | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Exceeds Revenue Expectations in Q1 | CSTL Stock News - GuruFocus
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Castle Biosciences to Acquire Previse for GI Test Expansion By Investing.com - Investing.com Canada
Castle Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Castle Biosciences Reports 21% Revenue Increase in Q1 2025 - TipRanks
Castle Biosciences to buy Previse (CSTL:NASDAQ) - Seeking Alpha
Castle Biosciences To Acquire Previse - marketscreener.com
Castle Biosciences Reports First Quarter 2025 Results - The Manila Times
Castle Biosciences to Acquire Previse | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse for GI Test Expansion - Investing.com
Castle Biosciences Reports First Quarter 2025 Results | CSTL Stock News - GuruFocus
BRIEF-Castle Biosciences Q1 Basic EPS USD -0.9 - TradingView
Castle Biosciences to Acquire Previse - Benzinga
Castle Biosciences Acquires Johns Hopkins-Backed GI Health Company Previse to Transform Cancer Detection - Stock Titan
Wells Fargo & Company MN Boosts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Barclays PLC Sells 3,288 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Invesco Ltd. Raises Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday - Defense World
New Data at DDW 2025 Further Demonstrates the TissueCypher® - GlobeNewswire
New Clinical Data Reveals How TissueCypher Test Could Transform Early Esophageal Cancer Detection - Stock Titan
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
2.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):